Human parvovirus PARV4 in clotting factor VIII concentrates

Vox Sanguinis

Volumn 93, Issue 4, 2007, Pages 341-347

  Fryer, J F ^a   Hubbard, A R ^a   Baylis, S A ^a  

^a NATIONAL INSTITUTE FOR BIOLOGICAL STANDARDS AND CONTROL   (United Kingdom)

Author keywords

Factor VIII; Genotype; PARV4; PARV5; Parvovirus; Virus contamination

Indexed keywords

BLOOD CLOTTING FACTOR 8;

ARTICLE; CONTROLLED STUDY; DNA DETERMINATION; DNA SEQUENCE; DRUG CONTAMINATION; DRUG MANUFACTURE; GENOTYPE; NONHUMAN; PARVOVIRUS; PARVOVIRUS4; PARVOVIRUS5; PRIORITY JOURNAL; VIRUS LOAD;

BIOLOGICAL PRODUCTS; DNA, VIRAL; DRUG CONTAMINATION; FACTOR VIII; HUMANS; PARVOVIRIDAE INFECTIONS; PARVOVIRUS; PLASMA; VIRAL LOAD;

EID: 36248979114     PISSN: 00429007     EISSN: 14230410     Source Type: Journal    
DOI: 10.1111/j.1423-0410.2007.00979.x     Document Type: Article

References (26)

1. Jones MS, Kapoor A, Lukashov VV, Simmonds P, Hecht F, Delwart E:New DNA viruses identified in patients with acute viral infection syndrome. J Virol 2005 79:8230 8236
2. Heegaard ED, Brown KE:Human parvovirus B19. Clin Microbiol Rev 2002 15:485 505
3. Koenigbauer UF, Eastlund T, Day JW:Clinical illness due to parvovirus B19 infection after infusion of solvent/detergent-treated pooled plasma. Transfusion 2000 40:1203 1206
4. Hayakawa F, Imada K, Towatari M, Saito H:Life-threatening human parvovirus B19 infection transmitted by intravenous immune globulin. Br J Haematol 2002 118:1187 1189
5. Laub R, Strengers P:Parvoviruses and blood products. Pathol Biol 2002 50:339 348
6. Wu C, Mason B, Jong J, Erdman D, McKernan L, Oakley M, Soucie M, Evatt B, Yu MW:Parvovirus B19 transmission by a high-purity factor VIII concentrate. Transfusion 2005 45:1003 1010
7. Baylis SA, Shah N, Minor PD:Evaluation of different assays for the detection of parvovirus B19 DNA in human plasma. J Virol Methods 2004 121:7 16
8. Fryer JF, Kapoor A, Minor PD, Delwart E, Baylis SA:Novel parvovirus and related variant in human plasma. Emerg Infect Dis 2006 12:151 154
9. Fryer JF, Delwart E, Hecht FM, Bernardin F, Jones MS, Shah N, Baylis SA:Frequent detection of the parvoviruses, PARV4 and PARV5, in plasma from blood donors and symptomatic individuals. Transfusion 2007 47:1054 1061
10. Fryer JF, Delwart E, Bernardin F, Tuke PW, Lukashov VV, Baylis SA:Analysis of two human parvovirus PARV4 genotypes identified in human plasma for fractionation. J Genl Virol 2007 88:2162 2167
11. Servant A, Laperche S, Lallemand F, Marinho V, De Saint Maur G, Meritet JF, Garbarg-Chenon A:Genetic diversity within human erythroviruses: identification of three genotypes. J Virol 2002 76:9124 9134
12. Chenna R, Sugawara H, Koike T, Lopez R, Gibson TJ, Higgins DG, Thompson JD:Multiple sequence alignment with the Clustal series of programs. Nucleic Acids Res 2003 31:3497 3500
13. Kumar S, Tamura K, Nei M:MEGA3: integrated software for molecular evolutionary genetics analysis and sequence alignment. Brief Bioinformatics 2004 5:150 163
14. van den Burg PJM, Vrielink H, Reesink HW:Donor selection: the exclusion of high risk donors? Vox Sang 1998 74:499 502
15. Guo ZP, Yu MW Hepatitis C virus RNA in factor VIII concentrates. Transfusion 1995 35:112 116
16. Roberts PL, Dunkerley C, McAuley A, Winkelman L:Effect of manufacturing process parameters on virus inactivation by dry heat treatment at 80°C in factor VIII. Vox Sang 2007 92:56 63
17. Horowitz MS, Rooks C, Horowitz B, Hilgartner MW:Virus safety of solvent/detergent-treated antihaemophilic factor concentrate. Lancet 1988 2:186 189
18. Horowitz B, Lazo A, Grossberg H, Page G, Lippin A, Swan G:Virus inactivation by solvent/detergent treatment and the manufacture of SD-plasma. Vox Sang 1998 74:203 206
19. Sofer G, Lister DC, Boose JA:Virus inactivation in the 1990s - and into the 21st century: Part 6, Inactivation methods grouped by virus. Biopharm Int 2003 April:42 68
20. Blümel J, Schmidt I, Willkommen H, Löwer J:Inactivation of parvovirus B19 during pasteurization of human serum albumin. Transfusion 2002 42:1011 1018
21. Boschetti N, Niederhauser I, Kempf C, Stühler A, Löwer J, Blümel J:Different susceptibility of B19 virus and mice minute virus to low pH treatment. Transfusion 2004 44:1079 1086
22. Prikhod'ko GG. Dry heat sensitivity of human B19 and porcine parvoviruses. Transfusion 2005 45:1692 1693
23. Roberts PL, El Hana C, Saldana J:Inactivation of parvovirus B19 and model viruses in factor VIII by dry heat treatment at 80°C. Transfusion 2006 46:1648 1650
24. Norja P, Hokynar K, Aaltonen L, Chen R, Ranki A, Partio EK, Kiviluto O, Davidkin I, Leivo T, Eis-Hübinger AM, Schneider B, Fischer H, Tolba R, Vapalahti O, Vaheri A, Söderlund-Venermo M, Hedman K:Bioportfolio: lifelong persistence of variant and prototypic erythrovirus DNA genomes in human tissue. Proc Natl Acad Sci 2006 103:7450 7453
25. Manning A, Willey SJ, Bell JE, Simmonds P:Comparison of tissue distribution, persistence, and molecular epidemiology of parvovirus B19 and novel human parvoviruses PARV4 and human bocavirus. J Infec Dis 2007 195:1345 1352
26. Fryer JF, Lucas SB, Padley D, Baylis SA:Parvoviruses PARV4/5 in hepatitis C virus-infected patient. Emerg Infect Dis 2007 13:175 176